Literature DB >> 7684192

Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma.

D N Shapiro1, M B Valentine, S T Rowe, A E Sinclair, J E Sublett, W M Roberts, A T Look.   

Abstract

We assessed fluorescence in situ hybridization (FISH) as an alternative to Southern blot analysis for determination of N-myc gene amplification in neuroblastoma. In the 44 pediatric solid tumor cell lines examined (20 neuroblastomas), the mean number of N-myc copies determined by FISH correlated closely with Southern blot results. There was wide intercellular variability in gene copy number in tumors that had evidence of amplification; however, tumors judged to be non-amplified completely lacked any cells with high N-myc copy number. FISH provided reliable estimates of N-myc amplification in 12 clinical samples even when the percentage of tumor was low. The other advantages of FISH over Southern blot analysis were speed and technical simplicity, ability to discern heterogeneous gene amplification among tumor cells in the same specimen, and capacity to determine the source of the amplified N-myc signal, whether extrachromosomal double-minute chromosomes, expanded intrachromosomal regions, or chromosome 2 aneuploidy. We conclude that FISH would refine the analysis of N-myc amplification in neuroblastoma and thus improve the assignment of patients to prognostic groups based on this unfavorable risk factor.

Entities:  

Mesh:

Year:  1993        PMID: 7684192      PMCID: PMC1886925     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome.

Authors:  E F Grady-Leopardi; M Schwab; A R Ablin; W Rosenau
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

2.  N-myc oncogene amplification in rhabdomyosarcoma at release.

Authors:  J A Garson; J Clayton; P McIntyre; J T Kemshead
Journal:  Lancet       Date:  1986-06-28       Impact factor: 79.321

3.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

4.  Different karyotypic patterns in early and advanced stage neuroblastomas.

Authors:  Y Kaneko; N Kanda; N Maseki; M Sakurai; Y Tsuchida; T Takeda; I Okabe; M Sakurai
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

5.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc.

Authors:  M Schwab; H E Varmus; J M Bishop; K H Grzeschik; S L Naylor; A Y Sakaguchi; G Brodeur; J Trent
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

6.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

Authors:  O P Kallioniemi; A Kallioniemi; W Kurisu; A Thor; L C Chen; H S Smith; F M Waldman; D Pinkel; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

7.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

8.  Expression and amplification of the N-myc gene in primary retinoblastoma.

Authors:  W H Lee; A L Murphree; W F Benedict
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

9.  Expression of cellular oncogenes in human malignancies.

Authors:  D J Slamon; J B deKernion; I M Verma; M J Cline
Journal:  Science       Date:  1984-04-20       Impact factor: 47.728

10.  Cytogenetic features of human neuroblastomas and cell lines.

Authors:  G M Brodeur; A A Green; F A Hayes; K J Williams; D L Williams; A A Tsiatis
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

View more
  30 in total

1.  Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines.

Authors:  X T Kong; V A Valentine; S T Rowe; M B Valentine; S T Ragsdale; B G Jones; D A Wilkinson; G M Brodeur; S L Cohn; A T Look
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study.

Authors:  Tara O Henderson; Smita Bhatia; Navin Pinto; Wendy B London; Patrick McGrady; Catherine Crotty; Can-Lan Sun; Susan L Cohn
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

4.  Assessment of fine needle aspiration cytology samples for molecular genetic analysis in neuroblastoma.

Authors:  Ankur Mandelia; Sandeep Agarwala; Arundhati Sharma; Venkateswaran K Iyer; Veereshwar Bhatnagar
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

5.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

Authors:  Julie R Park; Jeffrey R Scott; Clinton F Stewart; Wendy B London; Arlene Naranjo; Victor M Santana; Peter J Shaw; Susan L Cohn; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

6.  Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2.

Authors:  R Gururajan; J M Lahti; J Grenet; J Easton; I Gruber; P F Ambros; V J Kidd
Journal:  Genome Res       Date:  1998-09       Impact factor: 9.043

7.  Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

Authors:  Kevin Campbell; Derek Shyr; Rochelle Bagatell; Matthias Fischer; Akira Nakagawara; Adela Canete Nieto; Garrett M Brodeur; Katherine K Matthay; Wendy B London; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2019-05-21       Impact factor: 3.167

8.  Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells.

Authors:  L Savelyeva; R Corvi; M Schwab
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

10.  Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.

Authors:  Rochelle Bagatell; Maja Beck-Popovic; Wendy B London; Yang Zhang; Andrew D J Pearson; Katherine K Matthay; Tom Monclair; Peter F Ambros; Susan L Cohn
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.